These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 33290868)

  • 1. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
    Lanitis E; Rota G; Kosti P; Ronet C; Spill A; Seijo B; Romero P; Dangaj D; Coukos G; Irving M
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33156338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency.
    Guerrero JA; Klysz DD; Chen Y; Malipatlolla M; Lone J; Fowler C; Stuani L; May A; Bashti M; Xu P; Huang J; Michael B; Contrepois K; Dhingra S; Fisher C; Svensson KJ; Davis KL; Kasowski M; Feldman SA; Sotillo E; Mackall CL
    Nat Commun; 2024 Oct; 15(1):8658. PubMed ID: 39370422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
    Li Y; Hu Z; Li Y; Wu X
    Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T cells: the Chinese experience.
    Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
    Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
    Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
    Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Rubio MT; Galaine J; Borg C; Daguindau É
    Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
    Zhou D; Zhu X; Xiao Y
    Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
    Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches.
    Chaudhury A; Zhu X; Chu L; Goliaei A; June CH; Kearns JD; Stein AM
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S147-S159. PubMed ID: 33205434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.